Conventional myeloablative conditioning regimens for allografting rely on the use of toxic myeloablative and immunosuppressive therapies to achieve engraftment and control hematological neoplasia. Unfortunately, these regimens have resulted in substantial morbidity and mortality, and must be restricted to young patients in good medical condition. Clinical studies have shown that conditioning regimens can be reduced in intensity since the stem cell allograft can create its own space in the host's bone marrow. After obtaining approval of Institutional Review Board, we started a trial of reduced intensity conditioning (RIC) stem cell transplantation (RIST) in October 2002. In this single center retrospective study, we studied 20 adults with hematological malignancies, who received RIC prior to their first allograft. The median age of our patients was 50. 2 years. These patients demonstrated various diseases including 8 cases of malignant lymphoma. At 3 years, the probabilities of overall survival, progression free survival, relapse rate and transplant-related mortality rate were 57. 8, 46. 7, 31 and 30% for the whole cohort, respectively. Regarding engraftment of the donor's blood cells, the rate of white blood cell engraftment was 100%. Rate of platelet engraftment till day 50 after transplant was 94. 3%. The incidence of grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD were 44. 4 and 82. 1%, respectively. We then performed multivariate analysis of transplant related mortality. We concluded that the purpose of RIST was achieved, because age distribution and presence of organ dysfunctions did not significantly differ. We summarize satisfactory transplantation results were achieved with RIST, and their future indications' were promising.
View full abstract